In plain terms

The claim being assessed: CNS infection by specific pathogens is a necessary initiating event in a substantial fraction of sporadic Alzheimer's disease.

Where the evidence stands: Γ — Plausible mechanism. There is a believable biological story and partial support, but the causal step has not been demonstrated.

What this mechanism does: This makes the process worse or keeps it going, but something else starts it.

Strongest evidence for it: Γ for the preregistered SC3 etiologic gate. Scope-matched and primary-subclaim rules return Γ; weakest-link Β is shown separately for unverified enrichment/entry-order gates. No blanket Gamma cap is imposed on the vaccine/genetic/intervention set. The unmet positive burden is pathogen-specific CNS initiation with a measured substantial human fraction; dementia prevention, antimicrobial activity and imposed infection capability do not jointly measure it. Defined antimicrobial competence earns Ε and vaccine effects on recorded dementia receive full causal credit separately.

What decisive evidence would look like

In plain terms, researchers would change the proposed cause, confirm it changed as intended, and measure a meaningful health outcome while checking other explanations. The result should be able to support or count against the claim.

Relative explanatory fit: Alternative ranked ahead

What this review means for Infectious Hypothesis of Alzheimer's

Claim being assessed: CNS infection by specific pathogens is a necessary initiating event in a substantial fraction of sporadic Alzheimer's disease.. This review asks whether the proposed factor causes the health outcome—not just whether the two appear together. For the wording assessed here, the evidence is rated Plausible mechanism (HSEF Γ; Moderate confidence). There is a believable biological story and partial support, but the causal step has not been demonstrated. That rating applies to this claim and scope; it does not mean the biological process is irrelevant in every setting.

Implications for health and treatment: This is an assessment of a causal explanation, not proof that a particular supplement, diet, test, or treatment improves health. A treatment claim needs studies that test the intervention in people and measure meaningful benefits and harms. These findings can help frame research and informed clinical questions, but they do not identify what is right for one person.

Limits for individual care: Evidence from cells, animals, associations, or a plausible mechanism may not predict what happens in people. The grade is limited to the exact claim, outcomes, and sources reviewed, and it is not a diagnosis or an individual forecast. Do not start, stop, or change care based on this page; discuss personal decisions with a qualified clinician.

Medical information notice: This review provides general health information, not medical advice. It cannot diagnose a condition or replace an individual discussion with a qualified clinician.

This assessment rests on 65 sources and 70 individually checked claims. 70 of those claims were verified against the original paper.

A low grade is not an accusation. It means the causal work has not been done yet, which is the ordinary state of most actively studied mechanisms in biology.

At a glance

Sub-claims assessed separately

ID	Sub-claim	Type	Level	Pivotal card
SC1	Amyloid-beta can provide antimicrobial or pathogen-entrapment function.	mechanism	Ε	Card ↗
SC2	Specific pathogens are enriched in AD brains beyond controls.	existence	Β	Card ↗
SC3	CNS infection is necessary to initiate a substantial etiologic fraction of sporadic AD.	necessity	Γ	—
SC4	Pathogen entry precedes BBB failure and AD lesions.	mechanism	Β	—

Visual Evidence Cards · Pivotal Subclaims

Pivotal subclaim illustrations

Dark-theme simulated-micrograph renders and concise causal evidence summaries for the pivotal subclaims that govern this review's grade. Click any card to inspect the master 2400×2400 render.

Master 2400×2400 render ↗

Master 2400×2400 render ↗

Figures

Explanatory figures summarizing this review. They carry no evidential weight of their own; where a figure and the review differ, the review governs.

Full assessment

From here the review is written for a technical reader: caps and thresholds, competing models, the independence basis, and the citation ledger.

Sources: 65 primary reports; claims: 70; verified: 70; unverified: 0. Verification is bounded attribution. Access: 5 partial-body and 60 complete abstract/status examinations. Literature cutoff: 2026-10-05; source examination UTC date: 2026-10-06. No complete-paper audit or blinded calibration claimed. Adversarial review: Generated by Sol 6.1; adversarially reviewed by Claude Opus 5.5 (Anthropic) on 2026-10-06. 1 corrections applied (see ADVERSARIAL REVIEW AND APPROVAL). Status: Approved as revised.

AT A GLANCE

Infections can produce AD-like injury and vaccination can reduce dementia diagnoses; necessary CNS-pathogen initiation of a substantial sporadic AD fraction remains unestablished.

Deciding experiment: Predefine one pathogen, a susceptible sporadic population and an early time window, then follow CNS pathogen-positive and negative biomarker-negative participants with validated paired fluid/barrier and amyloid/tau measures; apply a selective prevention/removal instrument where feasible.

Belief versus evidence: Γ for the preregistered SC3 etiologic gate. Scope-matched and primary-subclaim rules return Γ; weakest-link Β is shown separately for unverified enrichment/entry-order gates. No blanket Gamma cap is imposed on the vaccine/genetic/intervention set. The unmet positive burden is pathogen-specific CNS initiation with a measured substantial human fraction; dementia prevention, antimicrobial activity and imposed infection capability do not jointly measure it. Defined antimicrobial competence earns Ε and vaccine effects on recorded dementia receive full causal credit separately.

Best-supported rival: Noninfectious APP/proteostasis contribution. Serial validated CNS pathogen/viability assays, barrier markers and amyloid/tau trajectories before symptoms, with a selective exposure/removal instrument, distinguish obligatory early infection from risk modification or secondary entry. Pathogen and time window must be fixed in advance.

COMPETING MECHANISTIC MODELS

Rank 1: Noninfectious APP/proteostasis contribution (Ε). APP processing and proteostasis can alter disease risk without demonstrating infection as an obligatory mediator. A673T human protection and reduced cleavage provide a molecular alternative (PMID22801501). This corpus does not adjudicate the entire amyloid cascade or show that infection never interacts with APP.

Rank 2: Sterile/systemic immune and vascular contribution (Γ). Systemic inflammatory and immune states can influence vulnerability without CNS pathogen initiation. AS01 cross-pathogen vaccine associations, terminal infection vascular differences and COVID biomarker shifts fit indirect routes (PMID40562756, PMID41319103, PMID39885359). These particular human mediators remain observational, and vaccine mechanisms are not resolved.

Rank 3: Secondary entry after barrier/lesion changes (Γ). Established pathology/barrier dysfunction permits microbial material to enter or persist. Late tissue and periodontitis-associated BBB disruption fit this ordering (PMID40684176, PMID39698934). Direct temporal human order is not measured and some imposed infections induce early pathology.

Rank 4: Bounded early infectious hit (Γ). A specified pathogen at a specified early stage triggers a later autonomous cascade. Latency/reactivation and transient Chlamydia models show a testable possibility (PMID30870531, PMID39772530, PMID25538615). Requires antecedent records and fixed time window; unlimited pathogen/time substitution is unfalsifiable.

Rank 5: Necessary CNS initiation in a substantial sporadic fraction (Γ). A CNS pathogen is an indispensable initiating event for a prespecified human fraction. Positive tissue studies, induced infection, antecedent serology and vaccine causal contrasts are the strongest assembled case. No necessary CNS mediator or attributable biomarker-confirmed AD fraction is established; assay replication and post-onset intervention failures remain material.

The tournament does not alter the nominal level. Compatible pathways and flexible alternatives are not automatically proved by explaining observations.

FULL REVIEW

Registered claim and scope

CNS infection by specific pathogens is a necessary initiating event in a substantial fraction of sporadic Alzheimer's disease.

SC3 is the etiologic necessity/initiation gate, preserving the earlier user-stated hypothesis. Antimicrobial competence, pathogen detection, dementia prevention and treatment after AD onset cannot substitute for necessary CNS-pathogen initiation. Refresh preserves the earlier frozen review.

Selection: public-interest rank 19 from the editorial ranking compiled 2026-09-23; categorical prior verdicts were visible. Private fresh review; earlier documents are preserved.

Evidence and causal interpretation

Human pathogen enrichment is neither uniformly absent nor uniformly established. Orthogonal Chlamydia and HSV observations support presence in some samples, while independent negatives and the HHV6 mapping/DDPCR dispute limit disease specificity. HCMV work has antibody controls and an AD-subset replication, but small cross-tissue selection and dissociated-organoid challenge do not establish the direction of a native initiating pathway (PMID9749980, PMID10878049, PMID29937276, PMID31983538, PMID39698934).

Antecedent IgM and genotype-conditioned associations differ from lifetime IgG and null Rotterdam incidence. All are peripheral proxies, and clinically nondemented enrollment can occur after the start of AD pathology. MR exposures represent cold sores/shingles/mononucleosis rather than CNS invasion; heterogeneous directions do not establish a universal virus instrument (PMID18982063, PMID25043910, PMID31914220, PMID33888766, PMID34560893).

Zoster eligibility discontinuities deserve causal credit for dementia diagnoses. Original Welsh Methods explicitly define any-cause dementia, separate eligibility from complier receipt estimates and allow VZV-independent immune effects. Australian and Canadian replication strengthen that endpoint without establishing a necessary CNS infection or biomarker-confirmed AD fraction; RSV/AS01 findings remain associational and challenge simple pathogen specificity (PMID40175543, PMID40267506, PMID41579903, PMID40562756).

VALAD randomized 120 HSV-seropositive early symptomatic participants and found worse primary cognition with valacyclovir, without amyloid/tau benefit. VALMCI was null in amyloid-positive MCI; earlier uncontrolled CSF drug exposure is feasibility rather than viral engagement. Antibiotic trial failure and strong observational antiviral associations coexist because exposure assignment, indication, endpoint and disease timing differ. These findings constrain ongoing treatment-responsive replication, not every prespecified cleared early hit (PMID41405855, PMID42210804, PMID35310522, PMID22718435, PMID42297456).

Experimental infection can alter amyloid, tau, neurons and cognition, but dose, route, strain and host architecture matter. Oral versus intracerebral Pg and Chlamydia mock/strain contrasts show direct counterexamples. Antimicrobial Aβ specificity and host protection are legitimate narrow functions; original homogenate experiments were partly bacteriostatic and sensitive to aggregation/assay conditions. Tau-null EV uptake is transfer rather than recipient templating (PMID30870531, PMID35328748, PMID17581756, PMID20209079, PMID27225182, PMID39189744).

HYPOTHESIS STATE EVALUATION FRAMEWORK (HSEF v5.3)

Subclaim matrix and aggregation

Preregistered aggregation: scope-matched. Γ for the preregistered SC3 etiologic gate. Scope-matched and primary-subclaim rules return Γ; weakest-link Β is shown separately for unverified enrichment/entry-order gates. No blanket Gamma cap is imposed on the vaccine/genetic/intervention set. The unmet positive burden is pathogen-specific CNS initiation with a measured substantial human fraction; dementia prevention, antimicrobial activity and imposed infection capability do not jointly measure it. Defined antimicrobial competence earns Ε and vaccine effects on recorded dementia receive full causal credit separately. Sensitivities: weakest-link Β; primary-subclaim Γ; scope-matched Γ.

Decisive-perturbation inventory and causal tally

[3] Intrathecal HSV antibodies were frequent in both AD and controls without significant group difference. Antibody indices imply prior intrathecal response rather than contemporary viable virus or disease-specific initiation; small sample limits negative inference.

[7] Rotterdam HSV IgG associated with cognitive decline but not incident dementia or AD. IgG lifetime exposure is insensitive to reactivation and CNS infection; null incidence does not exclude a specific susceptibility subgroup.

[8] Herpes-proxy Mendelian analyses gave heterogeneous results including positive mononucleosis and inverse shingles associations. Exposure instruments and family-history validation do not represent CNS invasion; pleiotropy and limited power restrict pathogen-specific causal attribution.

[10] Independent sequence screening and HHV6 PCR across brain repositories found little AD specificity. Original Methods/Results include PathSeq and triplex ddPCR, independent positive retesting and near-one-copy-per-cell integration patterns. MSBB/ROSMAP overlap positive reports; DNA assays add orthogonality but do not establish lifetime absence or a cleared early hit.

[11] Alternative reanalysis failed to reproduce HHV7 reads and found HHV6A in few high-ranked original samples, identifying low-specificity mapping. Same data are an assay-specific challenge rather than independent patients; negative reanalysis does not prove lifetime absence of infection.

[12] HHV6 antibodies, avidity and regional volumes did not distinguish AD, aMCI and controls. Serology does not detect localized CNS infection and cannot rule out every viral role despite the authors' stronger interpretation.

[15] Nested PCR and immunostaining in twenty AD cases failed to detect Chlamydia. Paraffin processing and limited tissue can reduce sensitivity; failure constrains common detectable presence, not every earlier exposure.

[16] Repeated PCR across up to six regions and culture failed unequivocal Chlamydia detection in AD/control brains. Fifteen cases and five controls are small; validated negative contemporary tissue does not test a prespecified cleared early-hit model.

[21] Multiple-target PCR and serology failed to support Borrelia involvement in examined AD samples. Small brain series cannot exclude every pathogen or cleared early exposure; this constrains the specific Borrelia claim.

[24] Welsh birth-date eligibility discontinuity supported reduced or delayed dementia diagnosis after live zoster vaccination. Original Methods define dementia of any cause, distinguish eligibility from instrument-scaled complier receipt effects, and consider clinical/subclinical VZV and pathogen-independent immune effects as compatible exploratory mechanisms. No CNS-pathogen-mediated biomarker-confirmed AD fraction is estimated.

[25] Australian birth-date vaccine eligibility reduced recorded dementia diagnoses with balanced baseline health and preventive-care controls. The eligibility effect is not the receipt effect; primary-care diagnoses lack AD/CNS mediation and the local age threshold limits transfer.

[26] Canadian eligibility discontinuities and cross-province comparisons supported delayed/reduced dementia diagnoses after live zoster vaccination. Multiple analyses share a Canadian source population; exposure uptake is separately surveyed and mechanism remains unspecified.

[27] Welsh eligibility analysis found effects on MCI diagnoses and dementia-related deaths after diagnosis. Same Welsh programme as prior report; nonspecific dementia effects and postdiagnosis benefit are incompatible with assuming only an initiation pathway.

[28] The US vaccine transition comparison associated recombinant vaccination with greater dementia-diagnosis-free time than live vaccination. Time-period/formulation changes and residual care differences remain; diagnosis-free time is not an incidence-risk percentage or direct CNS mediator.

[29] AS01-adjuvanted zoster and RSV vaccines associated similarly with lower short-term dementia risk. Propensity matching does not prove an adjuvant mechanism; different pathogens and short latency challenge unique CNS-infection attribution.

[31] VALAD valacyclovir worsened the primary cognitive outcome versus placebo and did not improve amyloid/tau PET in early symptomatic HSV-seropositive disease. Serology does not demonstrate CNS active replication; post-onset failure constrains this treatment/model, not a precisely specified cleared early initiating hit.

[32] VALMCI found no amyloid-PET, cognitive or functional benefit over twelve months in amyloid-positive HSV-seropositive MCI. Small pilot intervals admit limited effects; MCI with established amyloid is not prelesion prevention and active CNS infection was not the selection gate.

[34] Antibiotic combination reduced six-month cognitive decline in a small randomized trial but not significantly at twelve months. Chlamydia tests did not change, and antibiotics have non-antimicrobial effects; clinical signal does not isolate CNS infection initiation.

[35] DARAD failed cognitive/functional benefit from doxycycline/rifampin and showed deterioration with individual agents. Post-onset treatment and pathogen-unselected participants limit etiologic inference; does not exclude a prespecified earlier infection event.

[40] Replication-restricted viral strains and antivirals separated infection stages producing Aβ and phosphorylated tau. Aβ and tau had different replication dependencies; acute culture rescue cannot substitute for disease modification, as later human trials demonstrate.

[41] Repeated thermal reactivation of imposed HSV produced CNS replication, accumulated pathology and persistent cognitive deficits. Combined infection/stress and induced cycles do not demonstrate naturally initiated sporadic human AD or a necessity fraction.

[43] VZV alone induced inflammation without Aβ/tau but reactivated latent HSV with AD-like changes. Culture-specific reactivation supports an indirect possibility, not proven CNS VZV/HSV mediation of vaccination effects.

[44] Controlled injury reactivated latent HSV and increased AD-like changes; mock infection and IL1beta blockade separated contributing pathways. The initiating event in this model includes injury and imposed latent virus; pathway blockade in monolayers does not establish native human CNS necessity.

[45] Human HSV-associated proteins and organoid cGAS-STING-TBK1 perturbations linked phosphorylation with protection against infected-neuron death. Protective acute p-tau response is not beneficial chronic tangle deposition; postmortem association and induced infection do not order AD initiation.

[46] HSV-associated Aβ localization differed between 2D infected cells and 3D surrounding cells. Architecture-dependent induction is not uniform direct viral amyloid seeding; developmental organoids cannot establish clinical necessity.

[48] Human gingipain associations and imposed oral infection/inhibitor experiments supported a causal Pg injury pathway in mice. Tissue association and pharmacologic rescue in imposed infection do not establish naturally necessary CNS Pg infection; systemic inflammation and off-target effects require controls.

[50] Oral infection did not accelerate amyloid in CRND8 mice; live intracerebral Pg increased deposition whereas heat-killed inoculation did not. Direct brain injection bypasses entry/barrier questions; null oral effects are context-specific and do not exclude other pathogens or strains.

[53] Independent Chlamydia model found Aβ aggregates in infected, mock and untreated mice with unlike transgenic plaque morphology. Strain and assay differences limit an absolute negative conclusion; the experiment rejects unqualified infection-specific plaque induction in this setting.

[54] Laboratory Chlamydia infection caused limited olfactory persistence and transient amyloid changes that resolved as antigen burden fell. Strain-specific resolution differs from sustained human AD and does not demonstrate pathogen requirement for a sporadic fraction.

[55] Intranasal Chlamydia rapidly invaded peripheral nerves/CNS and produced adjacent Aβ changes; nasal injury altered peripheral infection. Capability to traverse nerves is not a human incidence-risk measurement; imposed dose and injury do not establish entry before native AD/barrier lesions.

[56] Low-grade candidemia induced glial granulomas, APP/Aβ-associated clearance and transient memory deficits, while Aβ enhanced antifungal phagocytosis. Acute clearing cerebritis is not chronic sporadic AD; APP and microglial effects do not isolate beneficial plaque deposition over decades.

[57] Whole-genome screening found partial HHV6 integration signals enriched in synucleinopathy cohorts rather than AD. Blood/genomic integration is not active CNS infection; low PathSeq signals need orthogonal validation and do not determine lifetime exposure.

[58] CSF sequencing with spike-ins and meningitis controls found negligible bacterial content consistent with contamination rather than a resident microbiome. CSF negatives do not exclude focal tissue infection or prior cleared infection; sequencing limits must remain prespecified.

[61] APP A673T protection paired with reduced beta cleavage provides a human molecular alternative to obligatory infection initiation. Rare genetic protection does not prove pathogens never contribute; no direct pathogen measurement or selective antimicrobial mediator was tested.

[62] Synthetic Aβ and AD homogenates inhibited microbes; Aβ immunodepletion reduced homogenate antimicrobial activity. Original Results find predominantly bacteriostatic Aβ effects with later growth recovery; Methods note diffusion/aggregation problems in agar assays and pooled homogenate immunodepletion. Concentration/aggregation and APP-containing antibody specificity limit physiological interpretation; chronic plaques and initiating infection are separate claims.

[63] Aβ-expressing mouse/worm systems showed microbial protection, with fibril-associated entrapment after imposed brain challenge. Transgenes and intracerebral challenge establish bounded antimicrobial competence; neither protective deposition in sporadic AD nor a necessary initiating pathogen follows.

Tally: 36 discriminating contrasts. Null and negative contrasts are discriminators, not positive threshold crossings. Reports and replications are not independent causal lines. Natural experiment estimates differ for eligibility and vaccine receipt. Prediagnostic samples can follow preclinical AD lesions. Antibody staining controls validate assay performance without proving viable initiating infection.

Cap audit, precedence and Β/Γ/Δ boundary

Rubric01 credits rigorous natural experiments and hard clinical interventions. Welsh/Australian/Canadian eligibility designs cross causal thresholds for their dementia endpoint and are not dismissed as observational. Antimicrobial/challenge experiments cross narrow functional thresholds, while human serology and late tissue do not supply CNS initiation. The assembled set is assessed together without re-capping it as exogenous-only; missing pathogen-specific temporal mediation and fraction attribution stop the registered scope. Post-onset failures cannot refute a bounded earlier hit, but neither can an unspecified hit evade all negative evidence.

Gamma hard-rule audit: Organoid/in-vitro and imposed CNS infection alone cannot establish natural sporadic human initiation. Pathogen-negative late tissue is bounded by sensitivity and time; it does not automatically disprove a prespecified cleared early hit. Natural vaccine contrasts are valid causal dementia evidence but have unresolved CNS-pathogen/AD mediation. Neither an unethical human infection RCT requirement nor a weakest-class cap is imposed on convergent evidence.

SC2 cap: “association without temporal or perturbational proof caps at Β.” Several pathogens or components are reported in AD brains, but reproducibility and specificity differ. HSV controls, HHV read-mapping/DDPCR challenges, failed Chlamydia/Borrelia replication, inherited integration and contamination remain. For the registered contamination-controlled human enrichment scope, associations do not establish a reproducible initiating burden.

SC4 cap: “association without temporal or perturbational proof caps at Β.” Prediagnostic serology and repeated infection models offer temporal clues, yet peripheral positivity and clinical diagnosis precede neither proven BBB failure nor first AD lesions. Late autopsies, tissue localization and plasma biomarker shifts do not directly order CNS pathogen entry before preclinical pathology.

SC1 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: yes. Synthetic/homogenate specificity and mouse/worm infection outcomes support antimicrobial or entrapment competence in defined models. Acute host protection is credited without equating it with beneficial chronic human plaque deposition; physiologic exposure and chronic tradeoffs prevent stronger broad inference.

SC2 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Several pathogens or components are reported in AD brains, but reproducibility and specificity differ. HSV controls, HHV read-mapping/DDPCR challenges, failed Chlamydia/Borrelia replication, inherited integration and contamination remain. For the registered contamination-controlled human enrichment scope, associations do not establish a reproducible initiating burden.

SC3 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Native human necessity and an attributable substantial fraction have not been demonstrated. Mechanistic infection models and vaccine natural experiments exceed mere colocalization, but they do not locate the causal mediator in CNS infection before AD. Post-onset valacyclovir failure is bounded counterevidence to ongoing treatable HSV replication, not proof against every prespecified earlier hit.

SC4 field-valid definition: “ - Endogenous genetic deletion, suppression, or degron depletion of the proposed mediator in vivo - Selective pathway inhibition that changes onset/progression while preserving broader viability - Vagotomy-type natural experiment, only if confounding is rigorously controlled AND effect is disease-initiation relevant rather than merely associated” Positive full-scope result: no. Prediagnostic serology and repeated infection models offer temporal clues, yet peripheral positivity and clinical diagnosis precede neither proven BBB failure nor first AD lesions. Late autopsies, tissue localization and plasma biomarker shifts do not directly order CNS pathogen entry before preclinical pathology.

Upward threshold ladder

SC1 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: yes.

SC1 Ε: “Requires causal support in a defined context, but with clear restriction by subtype, disease stage, model, or tissue.

Use Ε when there is a real causal contribution, but generalization to the entire disease class fails.” Satisfied: yes.

SC1 Ζ: “Requires: - Multiple independent causal lines in vivo - Replication across at least two relevant systems - Narrowing of major alternative models” Satisfied: no. Physiologic peptide-specific loss/restoration changes pathogen clearance and host injury without broader APP/immune disruption, replicated with chronic outcome tradeoffs.

SC2 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Independent blinded tissue and ante-mortem sampling with spike-ins, extraction blanks, localization and viable/transcriptional evidence reproducibly identifies pathogen enrichment beyond controls.

SC3 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. An antecedent CNS-pathogen-positive, biomarker-negative cohort and selective removal/prevention instrument reduce biomarker-confirmed AD conversion with mediator attribution and a prespecified substantial fraction, replicated independently.

SC4 Δ: “Requires at least one genuine causal perturbation in a disease-relevant in vivo system, or equivalent human natural experiment that materially supports the mechanism.” Satisfied: no. Paired longitudinal CNS pathogen, BBB and amyloid/tau measurements with validated sensitivity establish entry before lesions and barrier failure rather than inference from motor/cognitive diagnosis.

Upper ladder: Herpes-proxy MR, APP human protection, three national vaccine natural experiments and randomized antimicrobial clinical outcomes were examined. Genetics do not instrument antecedent CNS invasion; vaccines measure recorded dementia; post-onset antivirals lack selected CNS-replication mediation and fail benefit. They remain credible upper-ladder candidates without proving SC3. No unethical infection RCT is required.

Independence: 65 fresh report examinations are not 65 independent causal lines. AMP-AD/ROSMAP archives, Welsh reanalysis, US vaccine databases, related neural culture platforms and Chlamydia programmes are identified. Independent-country vaccine effects strengthen a dementia effect while shared endpoint/mediator ambiguity persists.

Human detection and assay challenge [9, 10, 16, 58]: Different molecular assays expose specificity/contamination errors, although some biological samples overlap.

Antecedent population exposure [4, 6, 7]: Adds temporal clinical follow-up but shares peripheral exposure and preclinical reverse-causation limits.

Vaccination quasi-experiments [24, 25, 26]: Independent health systems reduce ordinary healthy-user confounding; they do not resolve the common mediator.

Targeted post-onset interventions [31, 32, 35]: Randomization tests clinical benefit of distinct antimicrobial regimens at specified stages, not every early initiating model.

Falsification and pitfalls

Specific detection is not reproducible across assays. PMID31983538 and PMID32336252 challenge HHV assignments; PMID10655406 and PMID10878049 challenge common Chlamydia detection. Additional downgrade: False.

Peripheral infection fails imposed amyloid acceleration. PMID35328748 and PMID17581756 constrain unqualified sufficiency in tested systems. Additional downgrade: False.

Post-onset antimicrobial benefit fails. VALAD cognitive worsening, VALMCI null and DARAD failure reject these specific treatment predictions. Additional downgrade: False.

Dementia effect relabelled biomarker-confirmed AD prevention. Vaccination and claims analyses.

Peripheral serology relabelled CNS active infection. Cohorts and valacyclovir enrollment.

Entry after lesions treated as necessary initiation. Late autopsy localization and BBB changes.

Antimicrobial peptide competence treated as beneficial plaques. Aβ culture/challenge studies.

EV uptake treated as recipient tau templating. Tau-null recipient experiment.

Unlimited early-hit rescue after every negative study. Models lacking fixed pathogen and time window.

Adversarial steelman: above, then below

Δ is attractive because causal vaccine effects, mouse inhibitor rescue and recurrent infection are real. For the registered necessary CNS-initiation fraction, it would require an endogenous or equivalent human mediator test tied to prelesion AD conversion; the existing endpoints cannot supply that missing identification.

Β would undercredit the actual challenge pathways, antimicrobial specificity and rigorous vaccine/interventional discrimination. The necessary initiating mechanism is biologically testable and more than a tissue-colocalization narrative.

Γ preserves mechanistic plausibility while refusing to replace the registered necessary human CNS gate with risk modification or challenge capability. Defined antimicrobial competence and dementia-prevention effects remain separately credited.

Final score, causal direction and M/S/D

Γ for the preregistered SC3 etiologic gate. Scope-matched and primary-subclaim rules return Γ; weakest-link Β is shown separately for unverified enrichment/entry-order gates. No blanket Gamma cap is imposed on the vaccine/genetic/intervention set. The unmet positive burden is pathogen-specific CNS initiation with a measured substantial human fraction; dementia prevention, antimicrobial activity and imposed infection capability do not jointly measure it. Defined antimicrobial competence earns Ε and vaccine effects on recorded dementia receive full causal credit separately.

The supported disease-relevant role is context-dependent acceleration or inflammatory reinforcement in imposed infection systems, with a possible human risk contribution. Human CNS initiating necessity/rate limitation is not established; secondary entry remains possible but not proven as the sole ordering.

Momentum: Mechanistic only. The named programmes in this corpus — the Welsh, Australian and Canadian zoster-vaccine eligibility natural experiments, the VALAD and VALMCI randomized antiviral trials, and recent periodontitis and HCMV tissue work — are completed and published rather than running. No presently recruiting study addressing the SC3 boundary check, an antecedent CNS-pathogen-positive and biomarker-negative cohort with a selective prevention or removal instrument, is identified.

Stability: Stable. No named pending result is asserted to be likely to move the registered score imminently.

Divergence: Contested; no single implied-level arithmetic. These dimensions do not change level or confidence.

PROPOSED DECISIVE EXPERIMENTS

Predefine one pathogen, a susceptible sporadic population and an early time window, then follow CNS pathogen-positive and negative biomarker-negative participants with validated paired fluid/barrier and amyloid/tau measures; apply a selective prevention/removal instrument where feasible.

Readout: Biomarker-confirmed incident AD, functional trajectory and CNS mediator clearance before conversion. Controls: Extraction blanks/spike-ins, active systemic versus CNS infection, immune off-target effects, pathogen-negative participants and negative-control diagnoses. Supporting: Selective antecedent CNS clearance changes conversion with measured mediation and a replicated prespecified attributable fraction. Falsifying: Clearance affects infection but not AD conversion, or CNS positivity begins only after lesions/barrier dysfunction.

RESEARCH TIMELINE

KNOWLEDGE GAPS

A quantitative substantial-fraction definition with a representative denominator.

Validated active CNS pathogen assays and prospective prelesion tissue/fluid timing.

Specific vaccination mediation separated from heterologous immunity and vascular effects.

Safe prelesion antiviral prevention with demonstrated CNS target engagement.

Physiologic Aβ antimicrobial loss/rescue and long-term injury/protection tradeoffs.

Independent laboratory replication with contamination, integration and host-genotype controls.

METHODS AND CONSENSUS CONTRIBUTION

Consensus was used through the signed-in browser for discovery, counterevidence, research-gap and timeline suggestions, and attempted checks of specific indexed full-text passages. Returned Methods/Results passages were reconciled with original-paper passages where available; failed retrievals, source substitutions and unverified aspects are recorded in the case reconciliation. Successful passage checks are distinguished from provider summaries. Provider screening counts, citation counts and meters were not used as primary counts or HSEF scores. This source log records access depth; it does not claim complete-paper or supplement review. The monthly API allowance was conserved: zero Consensus API calls in this batch.

REVIEWER NOTES

65 primary reports freshly retrieved/re-examined, five selected original body checks. Prior frozen infectious review preserved; reused raw body files are access caches and received new explicit examination receipts. Linked preprint updates are excluded from primary counts. Two Pro searches used; broad Consensus retrieval was review-heavy, exact checks correctly identified trial abstract-only access and vaccine indexed text. API zero; no Deep upgrade purchased. Exact v5.3 structural validation is separate from scientific peer review.

Search leads, reviews, protocols and correction notices do not pad the primary count. Downloaded XML does not earn examination credit. Linked notices remain attached; unexamined correction details limit inference. This is a coordinator source/claim consistency assessment, not independent blinded calibration.

ADVERSARIAL REVIEW AND APPROVAL

Authoring model: Sol 6.1. Adversarial reviewer: Claude Opus 5.5 (Anthropic). Date: 2026-10-06.

Scope of checks. All 65 reference PMIDs re-resolved against PubMed (65/65 correct for first author, title, journal and DOI; no retraction or expression of concern). Ten load-bearing claims spot-checked against primary abstracts: VALAD (120 randomized, 60 per arm, HSV-seropositive early symptomatic AD; greater cognitive worsening on valacyclovir, between-group ADAS-Cog difference 3.93, 95 per cent CI 1.03–6.83, P = .01; no amyloid or tau benefit), VALMCI (pilot in amyloid-positive MCI, null primary florbetapir SUVR), the Welsh zoster-vaccine regression discontinuity (3.5 percentage-point absolute and 20.0 per cent relative reduction in new dementia diagnoses over seven years, any-cause dementia endpoint), the Australian and Canadian replications, the Borrelia negative-replication report, and the antimicrobial-peptide and experimental-infection sources. Scoring logic re-derived independently before the existing letter was read.

Findings.

Rejected findings (checked, no change).

1. The zoster-vaccine natural experiments should lift the headline above Γ. Rejected on the review's own, correct reasoning: their endpoint is a recorded dementia diagnosis, not pathogen-specific CNS initiation of a measured fraction of biomarker-confirmed sporadic AD, and the Welsh analysis explicitly permits VZV-independent immune effects. The review already gives that evidence full causal credit for its own endpoint.
2. SC2 and SC4 at Β are too harsh. Checked against universal cap 2 ("Pure association evidence — however large, however replicated — cannot exceed Β") and the contamination/replication record cited; Β is forced for those two gates.
3. Scope-matched aggregation. SC3 matches the registered claim's scope and is Γ; primary-subclaim also returns Γ, and the weakest-link Β sensitivity is reported rather than hidden.
4. Reference 32 parses without a year in automated checks. The entry carries "2026 Apr-Jun 01" from the journal's issue designation; the record is correct.
5. Citation-year differences of ±1 between printed issue year and PubMed e-pub year (references 5, 23, 30, 35, 46, 59). Publication-convention difference, not an error.

Residual limitations. Verification depth is bounded by access: 5 partial-body examinations and 60 abstract/status examinations. Tissue-detection disputes were assessed from published reports only; no independent assay, contamination or raw-data audit was performed.

Approval: Following adversarial review and the corrections listed above, the revised document is approved. — Claude Opus 5.5 (Anthropic), 2026-10-06.

REFERENCES

1. Itzhaki RF, Lin WR, Shang D et al. Herpes simplex virus type 1 in brain and risk of Alzheimer's disease. Lancet (London, England). 1997. PMID 9014911. DOI: 10.1016/S0140-6736(96)10149-5. Access: abstract_metadata. Study: PMID9014911.

2. Wozniak MA, Mee AP, Itzhaki RF et al. Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques. The Journal of pathology. 2009. PMID 18973185. DOI: 10.1002/path.2449. Access: abstract_metadata. Study: PMID18973185.

3. Wozniak MA, Shipley SJ, Combrinck M et al. Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients. Journal of medical virology. 2005. PMID 15602731. DOI: 10.1002/jmv.20271. Access: abstract_metadata. Study: PMID15602731.

4. Letenneur L, Pérès K, Fleury H et al. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. PloS one. 2008. PMID 18982063. DOI: 10.1371/journal.pone.0003637. Access: abstract_metadata. Study: PMID18982063.

5. Lövheim H, Gilthorpe J, Adolfsson R et al. Reactivated herpes simplex infection increases the risk of Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2015. PMID 25043910. DOI: 10.1016/j.jalz.2014.04.522. Access: abstract_metadata. Study: PMID25043910.

6. Linard M, Letenneur L, Garrigue I et al. Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2020. PMID 31914220. DOI: 10.1002/alz.12008. Access: abstract_metadata. Study: PMID31914220.

7. Murphy MJ, Fani L, Ikram MK et al. Herpes simplex virus 1 and the risk of dementia: a population-based study. Scientific reports. 2021. PMID 33888766. DOI: 10.1038/s41598-021-87963-9. Access: abstract_metadata. Study: PMID33888766.

8. Huang SY, Yang YX, Kuo K et al. Herpesvirus infections and Alzheimer's disease: a Mendelian randomization study. Alzheimer's research & therapy. 2021. PMID 34560893. DOI: 10.1186/s13195-021-00905-5. Access: abstract_metadata. Study: PMID34560893.

9. Readhead B, Haure-Mirande JV, Funk CC et al. Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus. Neuron. 2018. PMID 29937276. DOI: 10.1016/j.neuron.2018.05.023. Access: full_text_partial. Study: AMPAD-MSBB-ROSMAP-Mayo.

10. Allnutt MA, Johnson K, Bennett DA et al. Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts. Neuron. 2020. PMID 31983538. DOI: 10.1016/j.neuron.2019.12.031. Access: full_text_partial. Study: AMPAD-MSBB-ROSMAP-plus-JHBRC.

11. Chorlton SD et al. Reanalysis of Alzheimer's brain sequencing data reveals absence of purported HHV6A and HHV7. Journal of bioinformatics and computational biology. 2020. PMID 32336252. DOI: 10.1142/S0219720020500122. Access: abstract_metadata. Study: AMPAD-MSBB-reanalysis.

12. Agostini S, Mancuso R, Baglio F et al. Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer's disease. Journal of Alzheimer's disease : JAD. 2016. PMID 26444787. DOI: 10.3233/JAD-150464. Access: abstract_metadata. Study: PMID26444787.

13. Balin BJ, Gérard HC, Arking EJ et al. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Medical microbiology and immunology. 1998. PMID 9749980. DOI: 10.1007/s004300050071. Access: abstract_metadata. Study: PMID9749980.

14. Gérard HC, Dreses-Werringloer U, Wildt KS et al. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. FEMS immunology and medical microbiology. 2006. PMID 17052268. DOI: 10.1111/j.1574-695X.2006.00154.x. Access: abstract_metadata. Study: PMID17052268.

15. Gieffers J, Reusche E, Solbach W et al. Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients. Journal of clinical microbiology. 2000. PMID 10655406. DOI: 10.1128/JCM.38.2.881-882.2000. Access: abstract_metadata. Study: PMID10655406.

16. Ring RH, Lyons JM et al. Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain. Journal of clinical microbiology. 2000. PMID 10878049. DOI: 10.1128/JCM.38.7.2591-2594.2000. Access: abstract_metadata. Study: PMID10878049.

17. Poole S, Singhrao SK, Kesavalu L et al. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. Journal of Alzheimer's disease : JAD. 2013. PMID 23666172. DOI: 10.3233/JAD-121918. Access: abstract_metadata. Study: PMID23666172.

18. Sparks Stein P, Steffen MJ, Smith C et al. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2012. PMID 22546352. DOI: 10.1016/j.jalz.2011.04.006. Access: abstract_metadata. Study: PMID22546352.

19. Beydoun MA, Beydoun HA, Hossain S et al. Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer's Disease Dementia in a Large National Survey. Journal of Alzheimer's disease : JAD. 2020. PMID 32280099. DOI: 10.3233/JAD-200064. Access: abstract_metadata. Study: PMID32280099.

20. Riviere GR, Riviere KH, Smith KS et al. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Oral microbiology and immunology. 2002. PMID 11929559. DOI: 10.1046/j.0902-0055.2001.00100.x. Access: abstract_metadata. Study: PMID11929559.

21. Gutacker M, Valsangiacomo C, Balmelli T et al. Arguments against the involvement of Borrelia burgdorferi sensu lato in Alzheimer's disease. Research in microbiology. 1998. PMID 9766207. DOI: 10.1016/s0923-2508(97)83621-2. Access: abstract_metadata. Study: PMID9766207.

22. Pisa D, Alonso R, Rábano A et al. Different Brain Regions are Infected with Fungi in Alzheimer's Disease. Scientific reports. 2015. PMID 26468932. DOI: 10.1038/srep15015. Access: abstract_metadata. Study: PMID26468932.

23. Readhead BP, Mastroeni DF, Wang Q et al. Alzheimer's disease-associated CD83(+) microglia are linked with increased immunoglobulin G4 and human cytomegalovirus in the gut, vagal nerve, and brain. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2025. PMID 39698934. DOI: 10.1002/alz.14401. Access: full_text_partial. Study: PMID39698934.

24. Eyting M, Xie M, Michalik F et al. A natural experiment on the effect of herpes zoster vaccination on dementia. Nature. 2025. PMID 40175543. DOI: 10.1038/s41586-025-08800-x. Access: full_text_partial. Study: Welsh-zoster-eligibility.

25. Pomirchy M, Bommer C, Pradella F et al. Herpes Zoster Vaccination and Dementia Occurrence. JAMA. 2025. PMID 40267506. DOI: 10.1001/jama.2025.5013. Access: abstract_metadata. Study: PMID40267506.

26. Pomirchy M, Chung S, Bommer C et al. Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments. The Lancet. Neurology. 2026. PMID 41579903. DOI: 10.1016/S1474-4422(25)00455-7. Access: abstract_metadata. Study: PMID41579903.

27. Xie M, Eyting M, Bommer C et al. The effect of shingles vaccination at different stages of the dementia disease course. Cell. 2025. PMID 41338191. DOI: 10.1016/j.cell.2025.11.007. Access: abstract_metadata. Study: Welsh-zoster-eligibility.

28. Taquet M, Dercon Q, Todd JA et al. The recombinant shingles vaccine is associated with lower risk of dementia. Nature medicine. 2024. PMID 39053634. DOI: 10.1038/s41591-024-03201-5. Access: abstract_metadata. Study: US-TriNetX-vaccine-programme.

29. Taquet M, Todd JA, Harrison PJ et al. Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections. NPJ vaccines. 2025. PMID 40562756. DOI: 10.1038/s41541-025-01172-3. Access: abstract_metadata. Study: US-TriNetX-vaccine-programme.

30. Tang E, Ray I, Arnold BF et al. Recombinant zoster vaccine and the risk of dementia. Vaccine. 2025. PMID 39733478. DOI: 10.1016/j.vaccine.2024.126673. Access: abstract_metadata. Study: PMID39733478.

31. Devanand DP, Wisniewski T, Razlighi Q et al. Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial. JAMA. 2026. PMID 41405855. DOI: 10.1001/jama.2025.21738. Access: abstract_metadata. Study: PMID41405855.

32. Devanand DP, Huey ED, Qian M et al. Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial. Alzheimer disease and associated disorders. 2026 Apr-Jun 01. PMID 42210804. DOI: 10.1097/WAD.0000000000000735. Access: abstract_metadata. Study: PMID42210804.

33. Weidung B, Hemmingsson ES, Olsson J et al. VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease. Alzheimer's & dementia (New York, N. Y.). 2022. PMID 35310522. DOI: 10.1002/trc2.12264. Access: abstract_metadata. Study: PMID35310522.

34. Loeb MB, Molloy DW, Smieja M et al. A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease. Journal of the American Geriatrics Society. 2004. PMID 14962152. DOI: 10.1111/j.1532-5415.2004.52109.x. Access: abstract_metadata. Study: PMID14962152.

35. Molloy DW, Standish TI, Zhou Q et al. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial. International journal of geriatric psychiatry. 2013. PMID 22718435. DOI: 10.1002/gps.3846. Access: abstract_metadata. Study: PMID22718435.

36. Tzeng NS, Chung CH, Lin FH et al. Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 2018. PMID 29488144. DOI: 10.1007/s13311-018-0611-x. Access: abstract_metadata. Study: PMID29488144.

37. Alghamdi A, Balafas S, Bos JHJ et al. Association between the use of anti-herpetic drugs and subsequent initiation of Alzheimer's disease drug treatment: Dutch population-based inception cohort study. BMJ open. 2026. PMID 42297456. DOI: 10.1136/bmjopen-2025-114033. Access: abstract_metadata. Study: PMID42297456.

38. Wozniak MA, Itzhaki RF, Shipley SJ et al. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neuroscience letters. 2007. PMID 17980964. DOI: 10.1016/j.neulet.2007.09.077. Access: abstract_metadata. Study: PMID17980964.

39. Wozniak MA, Frost AL, Itzhaki RF et al. Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1. Journal of Alzheimer's disease : JAD. 2009. PMID 19221424. DOI: 10.3233/JAD-2009-0963. Access: abstract_metadata. Study: PMID19221424.

40. Wozniak MA, Frost AL, Preston CM et al. Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PloS one. 2011. PMID 22003387. DOI: 10.1371/journal.pone.0025152. Access: abstract_metadata. Study: PMID22003387.

41. De Chiara G, Piacentini R, Fabiani M et al. Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS pathogens. 2019. PMID 30870531. DOI: 10.1371/journal.ppat.1007617. Access: abstract_metadata. Study: PMID30870531.

42. Cairns DM, Rouleau N, Parker RN et al. A 3D human brain-like tissue model of herpes-induced Alzheimer's disease. Science advances. 2020. PMID 32494701. DOI: 10.1126/sciadv.aay8828. Access: abstract_metadata. Study: PMID32494701.

43. Cairns DM, Itzhaki RF, Kaplan DL et al. Potential Involvement of Varicella Zoster Virus in Alzheimer's Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1. Journal of Alzheimer's disease : JAD. 2022. PMID 35754275. DOI: 10.3233/JAD-220287. Access: abstract_metadata. Study: PMID35754275.

44. Cairns DM, Smiley BM, Smiley JA et al. Repetitive injury induces phenotypes associated with Alzheimer's disease by reactivating HSV-1 in a human brain tissue model. Science signaling. 2025. PMID 39772530. DOI: 10.1126/scisignal.ado6430. Access: abstract_metadata. Study: PMID39772530.

45. Hyde VR, Zhou C, Fernandez JR et al. Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer's disease. Cell reports. 2025. PMID 39753133. DOI: 10.1016/j.celrep.2024.115109. Access: abstract_metadata. Study: PMID39753133.

46. Abrahamson EE, Zheng W, Muralidaran V et al. Modeling Aβ42 Accumulation in Response to Herpes Simplex Virus 1 Infection: 2D or 3D? Journal of virology. 2021. PMID 33268524. DOI: 10.1128/JVI.02219-20. Access: abstract_metadata. Study: PMID33268524.

47. Bortolotti D, Gentili V, Rotola A et al. HHV-6A infection induces amyloid-beta expression and activation of microglial cells. Alzheimer's research & therapy. 2019. PMID 31831060. DOI: 10.1186/s13195-019-0552-6. Access: abstract_metadata. Study: PMID31831060.

48. Dominy SS, Lynch C, Ermini F et al. Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science advances. 2019. PMID 30746447. DOI: 10.1126/sciadv.aau3333. Access: abstract_metadata. Study: PMID30746447.

49. Ilievski V, Zuchowska PK, Green SJ et al. Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PloS one. 2018. PMID 30281647. DOI: 10.1371/journal.pone.0204941. Access: abstract_metadata. Study: PMID30281647.

50. Aravindraja C, Sakthivel R, Liu X et al. Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer's Disease Like Amyloid Pathology in APP-TgCRND8 Mice. International journal of molecular sciences. 2022. PMID 35328748. DOI: 10.3390/ijms23063328. Access: abstract_metadata. Study: PMID35328748.

51. Kong L, Li J, Gao L et al. Periodontitis-induced neuroinflammation triggers IFITM3-Aβ axis to cause alzheimer's disease-like pathology and cognitive decline. Alzheimer's research & therapy. 2025. PMID 40684176. DOI: 10.1186/s13195-025-01818-3. Access: abstract_metadata. Study: PMID40684176.

52. Little CS, Hammond CJ, MacIntyre A et al. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiology of aging. 2004. PMID 15013562. DOI: 10.1016/S0197-4580(03)00127-1. Access: abstract_metadata. Study: PMID15013562.

53. Boelen E, Stassen FR, van der Ven AJ et al. Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection. Acta neuropathologica. 2007. PMID 17581756. DOI: 10.1007/s00401-007-0252-3. Access: abstract_metadata. Study: PMID17581756.

54. Little CS, Joyce TA, Hammond CJ et al. Detection of bacterial antigens and Alzheimer's disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae. Frontiers in aging neuroscience. 2014. PMID 25538615. DOI: 10.3389/fnagi.2014.00304. Access: abstract_metadata. Study: PMID25538615.

55. Chacko A, Delbaz A, Walkden H et al. Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer's disease risk. Scientific reports. 2022. PMID 35177758. DOI: 10.1038/s41598-022-06749-9. Access: abstract_metadata. Study: PMID35177758.

56. Wu Y, Du S, Johnson JL et al. Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits. Nature communications. 2019. PMID 30610193. DOI: 10.1038/s41467-018-07991-4. Access: abstract_metadata. Study: PMID30610193.

57. Piotrowski SL, Allnutt MA, Johnson K et al. Herpesvirus genome integration in whole-genome sequences of dementia and control cohorts. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2026. PMID 41853978. DOI: 10.1002/alz.71047. Access: abstract_metadata. Study: PMID41853978.

58. Ward A, Park H, Cheng B et al. Cerebrospinal fluid microbiome revisited: no evidence of resident bacteria in archived samples. Microbiology spectrum. 2025. PMID 40960941. DOI: 10.1128/spectrum.01308-25. Access: abstract_metadata. Study: PMID40960941.

59. Milner O, Fisher RA, Asby DJ et al. Vessel-associated microglia are differentially activated and distributed in relation to systemic infection and Alzheimer's disease. Brain pathology (Zurich, Switzerland). 2026. PMID 41319103. DOI: 10.1111/bpa.70052. Access: abstract_metadata. Study: PMID41319103.

60. Duff EP, Zetterberg H, Heslegrave A et al. Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection. Nature medicine. 2025. PMID 39885359. DOI: 10.1038/s41591-024-03426-4. Access: abstract_metadata. Study: PMID39885359.

61. Jonsson T, Atwal JK, Steinberg S et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature. 2012. PMID 22801501. DOI: 10.1038/nature11283. Access: abstract_metadata. Study: PMID22801501.

62. Soscia SJ, Kirby JE, Washicosky KJ et al. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PloS one. 2010. PMID 20209079. DOI: 10.1371/journal.pone.0009505. Access: full_text_partial. Study: PMID20209079.

63. Kumar DK, Choi SH, Washicosky KJ et al. Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease. Science translational medicine. 2016. PMID 27225182. DOI: 10.1126/scitranslmed.aaf1059. Access: abstract_metadata. Study: PMID27225182.

64. Protto V, Miteva MT, Iannuzzi F et al. HSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles. mBio. 2024. PMID 39189744. DOI: 10.1128/mbio.01522-24. Access: abstract_metadata. Study: PMID39189744.

65. Liu Y, Johnston C, Jarousse N et al. Association between herpes simplex virus type 1 and the risk of Alzheimer's disease: a retrospective case-control study. BMJ open. 2025. PMID 40393802. DOI: 10.1136/bmjopen-2024-093946. Access: abstract_metadata. Study: PMID40393802.

Source-specific evidence cards

[1] Herpes simplex virus type 1 in brain and risk of Alzheimer's disease.

Shows: Brain HSV detection interacted with APOE4 in a small autopsy case-control series.

Does not show: HSV occurred in controls and some AD brains were negative; late tissue and wide intervals do not establish antecedent CNS necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[2] Herpes simplex virus type 1 DNA is located within Alzheimer's disease amyloid plaques.

Shows: In-situ PCR found plaque-associated HSV DNA in AD and aged normal brains, with different localization fractions.

Does not show: Plaque colocalization cannot order infection before deposition or distinguish entrapment from initiation; small autopsy assay samples constrain scope.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[3] Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer's disease patients.

Shows: Intrathecal HSV antibodies were frequent in both AD and controls without significant group difference.

Does not show: Antibody indices imply prior intrathecal response rather than contemporary viable virus or disease-specific initiation; small sample limits negative inference.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[4] Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study.

Shows: Baseline HSV IgM predicted incident AD in a fourteen-year dementia-free cohort; IgG did not significantly predict AD.

Does not show: Peripheral IgM is not a CNS mediator and prediagnosis is not prelesion; measured confounding control does not isolate an initiating infection.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[5] Reactivated herpes simplex infection increases the risk of Alzheimer's disease.

Shows: Swedish baseline HSV IgM predicted later AD whereas IgG did not.

Does not show: Age/sex-adjusted association and reactivation proxies cannot locate infection or demonstrate necessity; preclinical AD can precede sampling.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[6] Interaction between APOE4 and herpes simplex virus type 1 in Alzheimer's disease.

Shows: Bordeaux-3C HSV antibody proxies associated with AD in APOE4 carriers but not noncarriers.

Does not show: Wide genotype-stratum intervals and peripheral exposure do not verify a necessary CNS pathway; cohort estimates do not identify an etiologic fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[7] Herpes simplex virus 1 and the risk of dementia: a population-based study.

Shows: Rotterdam HSV IgG associated with cognitive decline but not incident dementia or AD.

Does not show: IgG lifetime exposure is insensitive to reactivation and CNS infection; null incidence does not exclude a specific susceptibility subgroup.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[8] Herpesvirus infections and Alzheimer's disease: a Mendelian randomization study.

Shows: Herpes-proxy Mendelian analyses gave heterogeneous results including positive mononucleosis and inverse shingles associations.

Does not show: Exposure instruments and family-history validation do not represent CNS invasion; pleiotropy and limited power restrict pathogen-specific causal attribution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[9] Multiscale Analysis of Independent Alzheimer's Cohorts Finds Disruption of Molecular, Genetic, and Clinical Networks by Human Herpesvirus.

Shows: Multicohort postmortem network analysis reported HHV6A/7 enrichment and regulatory associations with APP pathways.

Does not show: Original Methods use species-unique 31mers, sensitive local mapping and batch/cell covariates, yet independent reanalysis challenges assignment specificity. MSBB/ROSMAP shared archives and inherited integration complicate inference; modelled regulatory direction is not observed infection-before-AD.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 3:STAR Methods:paragraph14, 3:STAR Methods:paragraph15, 3:STAR Methods:paragraph16, 3:STAR Methods:paragraph17, 3:STAR Methods:paragraph18, 3:STAR Methods:paragraph24, 3:STAR Methods:paragraph20, 3:STAR Methods:paragraph21, 3:STAR Methods:paragraph22, 3:STAR Methods:paragraph23. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[10] Human Herpesvirus 6 Detection in Alzheimer's Disease Cases and Controls across Multiple Cohorts.

Shows: Independent sequence screening and HHV6 PCR across brain repositories found little AD specificity.

Does not show: Original Methods/Results include PathSeq and triplex ddPCR, independent positive retesting and near-one-copy-per-cell integration patterns. MSBB/ROSMAP overlap positive reports; DNA assays add orthogonality but do not establish lifetime absence or a cleared early hit.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results::paragraph2, 1:Results::paragraph3, 1:Results::paragraph5, 3:STAR Methods::paragraph2, 3:STAR Methods::paragraph3. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[11] Reanalysis of Alzheimer's brain sequencing data reveals absence of purported HHV6A and HHV7.

Shows: Alternative reanalysis failed to reproduce HHV7 reads and found HHV6A in few high-ranked original samples, identifying low-specificity mapping.

Does not show: Same data are an assay-specific challenge rather than independent patients; negative reanalysis does not prove lifetime absence of infection.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[12] Lack of evidence for a role of HHV-6 in the pathogenesis of Alzheimer's disease.

Shows: HHV6 antibodies, avidity and regional volumes did not distinguish AD, aMCI and controls.

Does not show: Serology does not detect localized CNS infection and cannot rule out every viral role despite the authors' stronger interpretation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[13] Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain.

Shows: Chlamydia DNA, culture, transcripts and microscopy were positive in many AD brains versus controls.

Does not show: Small late-autopsy series from one programme cannot order infection before lesions; independent failures of detection remain material.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[14] Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain.

Shows: Follow-up Chlamydia brain PCR and viable/transcriptional evidence extended the original positive programme.

Does not show: The abstract reports inconsistent AD sample denominators; no precise prevalence is carried forward without body resolution. Shared programme is not independent causal replication.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[15] Failure to detect Chlamydia pneumoniae in brain sections of Alzheimer's disease patients.

Shows: Nested PCR and immunostaining in twenty AD cases failed to detect Chlamydia.

Does not show: Paraffin processing and limited tissue can reduce sensitivity; failure constrains common detectable presence, not every earlier exposure.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[16] Failure to detect Chlamydia pneumoniae in the late-onset Alzheimer's brain.

Shows: Repeated PCR across up to six regions and culture failed unequivocal Chlamydia detection in AD/control brains.

Does not show: Fifteen cases and five controls are small; validated negative contemporary tissue does not test a prespecified cleared early-hit model.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[17] Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue.

Shows: Periodontal LPS immunostaining/immunoblotting identified four of ten AD brains and no controls.

Does not show: A virulence component is not proof of live CNS infection or entry before AD; surface adsorption and small tissue samples constrain specificity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[18] Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease.

Shows: Periodontal antibody differences preceded cognitive conversion in the Kentucky cohort.

Does not show: The significant taxa were Fusobacterium and Prevotella, not a uniquely demonstrated Pg CNS infection; antibody and oral-health confounding remain.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[19] Clinical and Bacterial Markers of Periodontitis and Their Association with Incident All-Cause and Alzheimer's Disease Dementia in a Large National Survey.

Shows: NHANES periodontal depth and multi-taxon antibody composites associated with later claims-based dementia and AD outcomes.

Does not show: Composite exposures, socioeconomic care and claims diagnosis cannot identify a necessary CNS species or fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[20] Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease.

Shows: Oral Treponema PCR and antigens were enriched in AD cortex and detected in some controls and trigeminal tissue.

Does not show: Cross-sectional localization is compatible with several entry directions; late presence does not prove initiating necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[21] Arguments against the involvement of Borrelia burgdorferi sensu lato in Alzheimer's disease.

Shows: Multiple-target PCR and serology failed to support Borrelia involvement in examined AD samples.

Does not show: Small brain series cannot exclude every pathogen or cleared early exposure; this constrains the specific Borrelia claim.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[22] Different Brain Regions are Infected with Fungi in Alzheimer's Disease.

Shows: Fungal staining and sequencing reported multiple fungal species in AD CNS regions versus controls.

Does not show: Low-biomass tissue, antibody cross-reactivity, reagent contamination and late entry need independent resolution; reported material is not antecedent necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[23] Alzheimer's disease-associated CD83(+) microglia are linked with increased immunoglobulin G4 and human cytomegalovirus in the gut, vagal nerve, and brain.

Shows: CD83 microglia, HCMV and IgG4 cross-tissue associations were replicated, and infected organoids showed AD-like changes.

Does not show: Original Methods identify selected 34 cortical, 25 colon and eight vagal Banner specimens, plus an AD-only ROSMAP validation subset; antibody peptide/positive-negative tissue controls are present. Organoid experiments use dissociated cells with imposed HCMV and 48-hour assays. Cross-tissue direction, viable human CNS infection and initiation remain unproved.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:METHODS:paragraph13, 1:METHODS:paragraph14, 1:METHODS:paragraph9, 1:METHODS:paragraph12, 1:METHODS:paragraph29, 2:RESULTS:paragraph0, 2:RESULTS:paragraph1. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[24] A natural experiment on the effect of herpes zoster vaccination on dementia.

Shows: Welsh birth-date eligibility discontinuity supported reduced or delayed dementia diagnosis after live zoster vaccination.

Does not show: Original Methods define dementia of any cause, distinguish eligibility from instrument-scaled complier receipt effects, and consider clinical/subclinical VZV and pathogen-independent immune effects as compatible exploratory mechanisms. No CNS-pathogen-mediated biomarker-confirmed AD fraction is estimated.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 6:Explorations of the effect mechanism:paragraph0, 6:Explorations of the effect mechanism:paragraph12, 8:Methods:paragraph8, 8:Methods:paragraph11, 8:Methods:paragraph12. No complete-paper or supplement audit claimed. UpdateOf: PMID37292746. Subclaims: SC3.

[25] Herpes Zoster Vaccination and Dementia Occurrence.

Shows: Australian birth-date vaccine eligibility reduced recorded dementia diagnoses with balanced baseline health and preventive-care controls.

Does not show: The eligibility effect is not the receipt effect; primary-care diagnoses lack AD/CNS mediation and the local age threshold limits transfer.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. UpdateOf: PMID38978672. Subclaims: SC3.

[26] Herpes zoster vaccination and incident dementia in Canada: an analysis of natural experiments.

Shows: Canadian eligibility discontinuities and cross-province comparisons supported delayed/reduced dementia diagnoses after live zoster vaccination.

Does not show: Multiple analyses share a Canadian source population; exposure uptake is separately surveyed and mechanism remains unspecified.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[27] The effect of shingles vaccination at different stages of the dementia disease course.

Shows: Welsh eligibility analysis found effects on MCI diagnoses and dementia-related deaths after diagnosis.

Does not show: Same Welsh programme as prior report; nonspecific dementia effects and postdiagnosis benefit are incompatible with assuming only an initiation pathway.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[28] The recombinant shingles vaccine is associated with lower risk of dementia.

Shows: The US vaccine transition comparison associated recombinant vaccination with greater dementia-diagnosis-free time than live vaccination.

Does not show: Time-period/formulation changes and residual care differences remain; diagnosis-free time is not an incidence-risk percentage or direct CNS mediator.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[29] Lower risk of dementia with AS01-adjuvanted vaccination against shingles and respiratory syncytial virus infections.

Shows: AS01-adjuvanted zoster and RSV vaccines associated similarly with lower short-term dementia risk.

Does not show: Propensity matching does not prove an adjuvant mechanism; different pathogens and short latency challenge unique CNS-infection attribution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[30] Recombinant zoster vaccine and the risk of dementia.

Shows: Large claims cohorts associated recombinant vaccine dose and antiviral exposure with lower dementia incidence.

Does not show: Healthy-user, treatment indication and diagnostic bias remain; no biomarker-defined AD or CNS infection mediates the reported association.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[31] Valacyclovir Treatment of Early Symptomatic Alzheimer Disease: The VALAD Randomized Clinical Trial.

Shows: VALAD valacyclovir worsened the primary cognitive outcome versus placebo and did not improve amyloid/tau PET in early symptomatic HSV-seropositive disease.

Does not show: Serology does not demonstrate CNS active replication; post-onset failure constrains this treatment/model, not a precisely specified cleared early initiating hit.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[32] Valacyclovir Treatment in Mild Cognitive Impairment: The VALMCI Randomized Clinical Trial.

Shows: VALMCI found no amyloid-PET, cognitive or functional benefit over twelve months in amyloid-positive HSV-seropositive MCI.

Does not show: Small pilot intervals admit limited effects; MCI with established amyloid is not prelesion prevention and active CNS infection was not the selection gate.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[33] VALZ-Pilot: High-dose valacyclovir treatment in patients with early-stage Alzheimer's disease.

Shows: Open VALZ pilot established short-term valacyclovir feasibility and CSF drug exposure with unchanged tau/NfL and improved MMSE.

Does not show: Uncontrolled four-week change is vulnerable to practice effects; CNS drug exposure is not measured viral suppression or disease modification.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[34] A randomized, controlled trial of doxycycline and rifampin for patients with Alzheimer's disease.

Shows: Antibiotic combination reduced six-month cognitive decline in a small randomized trial but not significantly at twelve months.

Does not show: Chlamydia tests did not change, and antibiotics have non-antimicrobial effects; clinical signal does not isolate CNS infection initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[35] A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.

Shows: DARAD failed cognitive/functional benefit from doxycycline/rifampin and showed deterioration with individual agents.

Does not show: Post-onset treatment and pathogen-unselected participants limit etiologic inference; does not exclude a prespecified earlier infection event.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[36] Anti-herpetic Medications and Reduced Risk of Dementia in Patients with Herpes Simplex Virus Infections-a Nationwide, Population-Based Cohort Study in Taiwan.

Shows: Taiwan claims associated clinically diagnosed HSV with dementia and antiviral prescriptions with a very large lower hazard.

Does not show: Indication, care access, time assignment and diagnosis biases can distort large effects; neither CNS infection nor AD biomarkers were the endpoint.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[37] Association between the use of anti-herpetic drugs and subsequent initiation of Alzheimer's disease drug treatment: Dutch population-based inception cohort study.

Shows: Dutch pharmacy exposure associated antivirals with markedly lower subsequent AD-drug initiation.

Does not show: Medication initiation is not confirmed AD incidence; unmeasured indication, time and care-selection bias remain, and no CNS mediator was measured.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[38] Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation.

Shows: Imposed HSV infection increased cellular secretases/Aβ and brain Aβ deposits.

Does not show: Induced infection establishes capability, not native sporadic initiation, selective vulnerability or an etiologic human fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[39] Alzheimer's disease-specific tau phosphorylation is induced by herpes simplex virus type 1.

Shows: HSV infection induced AD-associated tau phosphorylation and kinase activity in cells.

Does not show: AD-like epitopes under acute infection are not complete human AD causality or necessary initiating infection.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[40] Antivirals reduce the formation of key Alzheimer's disease molecules in cell cultures acutely infected with herpes simplex virus type 1.

Shows: Replication-restricted viral strains and antivirals separated infection stages producing Aβ and phosphorylated tau.

Does not show: Aβ and tau had different replication dependencies; acute culture rescue cannot substitute for disease modification, as later human trials demonstrate.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[41] Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice.

Shows: Repeated thermal reactivation of imposed HSV produced CNS replication, accumulated pathology and persistent cognitive deficits.

Does not show: Combined infection/stress and induced cycles do not demonstrate naturally initiated sporadic human AD or a necessity fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[42] A 3D human brain-like tissue model of herpes-induced Alzheimer's disease.

Shows: Imposed HSV in engineered human neural tissue produced plaque-like formations, inflammation and reduced function without added Aβ.

Does not show: Exogenous virus remains an imposed trigger; immature tissue and injury responses do not establish a human etiologic fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[43] Potential Involvement of Varicella Zoster Virus in Alzheimer's Disease via Reactivation of Quiescent Herpes Simplex Virus Type 1.

Shows: VZV alone induced inflammation without Aβ/tau but reactivated latent HSV with AD-like changes.

Does not show: Culture-specific reactivation supports an indirect possibility, not proven CNS VZV/HSV mediation of vaccination effects.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[44] Repetitive injury induces phenotypes associated with Alzheimer's disease by reactivating HSV-1 in a human brain tissue model.

Shows: Controlled injury reactivated latent HSV and increased AD-like changes; mock infection and IL1beta blockade separated contributing pathways.

Does not show: The initiating event in this model includes injury and imposed latent virus; pathway blockade in monolayers does not establish native human CNS necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[45] Anti-herpetic tau preserves neurons via the cGAS-STING-TBK1 pathway in Alzheimer's disease.

Shows: Human HSV-associated proteins and organoid cGAS-STING-TBK1 perturbations linked phosphorylation with protection against infected-neuron death.

Does not show: Protective acute p-tau response is not beneficial chronic tangle deposition; postmortem association and induced infection do not order AD initiation.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC2.

[46] Modeling Aβ42 Accumulation in Response to Herpes Simplex Virus 1 Infection: 2D or 3D?

Shows: HSV-associated Aβ localization differed between 2D infected cells and 3D surrounding cells.

Does not show: Architecture-dependent induction is not uniform direct viral amyloid seeding; developmental organoids cannot establish clinical necessity.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[47] HHV-6A infection induces amyloid-beta expression and activation of microglial cells.

Shows: High-inoculum HHV6A microglia infection increased Aβ42, activation and phosphorylated tau secretion.

Does not show: Imposed infection and immortalized/monocyte-derived microglia do not show endogenous neurodegeneration or human initiating infection.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[48] Porphyromonas gingivalis in Alzheimer's disease brains: Evidence for disease causation and treatment with small-molecule inhibitors.

Shows: Human gingipain associations and imposed oral infection/inhibitor experiments supported a causal Pg injury pathway in mice.

Does not show: Tissue association and pharmacologic rescue in imposed infection do not establish naturally necessary CNS Pg infection; systemic inflammation and off-target effects require controls.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC3.

[49] Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice.

Shows: Chronic imposed oral Pg in young wild-type mice produced brain microbial signals, inflammation, degenerating-neuron staining and Aβ/tau changes.

Does not show: Repeated exposure and small groups do not isolate CNS infection from systemic effects; NeuN expression alone is not cell death, though FluoroJade adds injury evidence.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[50] Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer's Disease Like Amyloid Pathology in APP-TgCRND8 Mice.

Shows: Oral infection did not accelerate amyloid in CRND8 mice; live intracerebral Pg increased deposition whereas heat-killed inoculation did not.

Does not show: Direct brain injection bypasses entry/barrier questions; null oral effects are context-specific and do not exclude other pathogens or strains.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[51] Periodontitis-induced neuroinflammation triggers IFITM3-Aβ axis to cause alzheimer's disease-like pathology and cognitive decline.

Shows: Pg periodontitis increased BBB permeability, glial IFITM3, amyloid and cognitive impairment in wild-type and APP/PS1 mice.

Does not show: The abstract does not document selective IFITM3 dependency/rescue; barrier disruption can precede or mediate microbial entry rather than CNS infection necessarily initiating AD.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[52] Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice.

Shows: An AD-brain Chlamydia isolate induced persistent olfactory infection and increasing Aβ-reactive deposits in BALB/c mice.

Does not show: Imposed infection and plaque-like staining do not establish a complete AD trajectory or naturally necessary human infection.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[53] Detection of amyloid beta aggregates in the brain of BALB/c mice after Chlamydia pneumoniae infection.

Shows: Independent Chlamydia model found Aβ aggregates in infected, mock and untreated mice with unlike transgenic plaque morphology.

Does not show: Strain and assay differences limit an absolute negative conclusion; the experiment rejects unqualified infection-specific plaque induction in this setting.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[54] Detection of bacterial antigens and Alzheimer's disease-like pathology in the central nervous system of BALB/c mice following intranasal infection with a laboratory isolate of Chlamydia pneumoniae.

Shows: Laboratory Chlamydia infection caused limited olfactory persistence and transient amyloid changes that resolved as antigen burden fell.

Does not show: Strain-specific resolution differs from sustained human AD and does not demonstrate pathogen requirement for a sporadic fraction.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[55] Chlamydia pneumoniae can infect the central nervous system via the olfactory and trigeminal nerves and contributes to Alzheimer's disease risk.

Shows: Intranasal Chlamydia rapidly invaded peripheral nerves/CNS and produced adjacent Aβ changes; nasal injury altered peripheral infection.

Does not show: Capability to traverse nerves is not a human incidence-risk measurement; imposed dose and injury do not establish entry before native AD/barrier lesions.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[56] Microglia and amyloid precursor protein coordinate control of transient Candida cerebritis with memory deficits.

Shows: Low-grade candidemia induced glial granulomas, APP/Aβ-associated clearance and transient memory deficits, while Aβ enhanced antifungal phagocytosis.

Does not show: Acute clearing cerebritis is not chronic sporadic AD; APP and microglial effects do not isolate beneficial plaque deposition over decades.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1, SC3.

[57] Herpesvirus genome integration in whole-genome sequences of dementia and control cohorts.

Shows: Whole-genome screening found partial HHV6 integration signals enriched in synucleinopathy cohorts rather than AD.

Does not show: Blood/genomic integration is not active CNS infection; low PathSeq signals need orthogonal validation and do not determine lifetime exposure.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[58] Cerebrospinal fluid microbiome revisited: no evidence of resident bacteria in archived samples.

Shows: CSF sequencing with spike-ins and meningitis controls found negligible bacterial content consistent with contamination rather than a resident microbiome.

Does not show: CSF negatives do not exclude focal tissue infection or prior cleared infection; sequencing limits must remain prespecified.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2.

[59] Vessel-associated microglia are differentially activated and distributed in relation to systemic infection and Alzheimer's disease.

Shows: Terminal systemic infection and AD associated with distinct vessel-associated microglial activation and vascular/barrier markers.

Does not show: Terminal infection and cross-sectional barrier changes are progression/confounding evidence, not infection-before-lesion order.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC2, SC4.

[60] Plasma proteomic evidence for increased β-amyloid pathology after SARS-CoV-2 infection.

Shows: Paired UK Biobank plasma before/after COVID showed AD-associated biomarker shifts, larger with vulnerability/severity.

Does not show: Plasma biomarkers and post-hoc matching do not establish incident AD or direct CNS invasion; systemic inflammation is a viable alternative.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3, SC4.

[61] A mutation in APP protects against Alzheimer's disease and age-related cognitive decline.

Shows: APP A673T protection paired with reduced beta cleavage provides a human molecular alternative to obligatory infection initiation.

Does not show: Rare genetic protection does not prove pathogens never contribute; no direct pathogen measurement or selective antimicrobial mediator was tested.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[62] The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide.

Shows: Synthetic Aβ and AD homogenates inhibited microbes; Aβ immunodepletion reduced homogenate antimicrobial activity.

Does not show: Original Results find predominantly bacteriostatic Aβ effects with later growth recovery; Methods note diffusion/aggregation problems in agar assays and pooled homogenate immunodepletion. Concentration/aggregation and APP-containing antibody specificity limit physiological interpretation; chronic plaques and initiating infection are separate claims.

Access/status: Complete primary abstract and linked-status metadata examined. Selected body sections: 1:Results:paragraph2, 1:Results:paragraph6, 3:Materials and Methods:paragraph6, 3:Materials and Methods:paragraph12. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[63] Amyloid-β peptide protects against microbial infection in mouse and worm models of Alzheimer's disease.

Shows: Aβ-expressing mouse/worm systems showed microbial protection, with fibril-associated entrapment after imposed brain challenge.

Does not show: Transgenes and intracerebral challenge establish bounded antimicrobial competence; neither protective deposition in sporadic AD nor a necessary initiating pathogen follows.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC1.

[64] HSV-1 infection induces phosphorylated tau propagation among neurons via extracellular vesicles.

Shows: HSV induced EV-associated phosphorylated tau and transfer into recipient neurons, including tau-null recipients.

Does not show: Uptake into tau-null cells is not recipient-templated seeding; acute infection, overexpressed tagged tau and transfer do not establish progressive native human AD.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

[65] Association between herpes simplex virus type 1 and the risk of Alzheimer's disease: a retrospective case-control study.

Shows: Matched US claims linked diagnosed HSV1 history with AD and antivirals with moderately lower risk.

Does not show: Clinically coded HSV is a small selected subset of common infection; residual care/indication bias and absent CNS mediator prevent causal fraction attribution.

Access/status: Complete primary abstract and linked-status metadata examined. No complete-paper or supplement audit claimed. none_found. Subclaims: SC3.

Documentary record

Every grade on this site is reproducible from its record. The files below are the posted edition exactly as assessed.

• SHA256.txt
• codex-correction-provenance.json
• consensus-addendum.md
• consensus-validation.json
• edition-approval-audit.json
• infectious-alz-ranked-refresh.review.md
• infectious-alz-ranked-refresh.scorecard.json
• validation-report.json
• validation-round2-2026-10-14.json
• validation.txt

Sources: 65 · load-bearing claims: 70 · verified: 70 · unverified: 0 · contradicted: 0 · schema 5.3